Why VolitionRx Limited’s (VNRX) Stock Is Up 5.28%
As of Monday, November 03, VolitionRx Limited’s VNRX share price has surged by 5.28%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Commentary & Analysis
Why VolitionRx Limited’s (VNRX) Stock Is Up 6.09%
As of Thursday, October 30, VolitionRx Limited’s VNRX share price has surged by 6.09%, which has investors questioning if this is right time to sell.Jenna Brashear
Why VolitionRx Limited’s (VNRX) Stock Is Down 21.25%
As of Friday, October 10, VolitionRx Limited’s VNRX share price has dipped by 21.25%, which has investors questioning if this is right time to buy.Omar Beirat
Why VolitionRx Limited’s (VNRX) Stock Is Down 5.35%
As of Thursday, October 09, VolitionRx Limited’s VNRX share price has dipped by 5.35%, which has investors questioning if this is right time to buy.Jenna Brashear
Why VolitionRx Limited’s (VNRX) Stock Is Up 5.10%
As of Friday, October 03, VolitionRx Limited’s VNRX share price has surged by 5.10%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | VNRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6.0 | $337.2 | 4% |
|
| Shares Out (Mil) | 6.9 | 41.9 | 17% |
|
| Institutional Ownership | 77.5% | 77.8% | 47% |
|
| Float (Mil) | 6.7 | 34.7 | 15% |
|
| Beta | 1.04 | 0.85 | 62% |
|
| Avg Daily Volume (000s) | 347 | 278 | 53% |
|
| Price Change (52-week) |
(94.9%) | 58.7% | 2% |
|
| Growth | VNRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | (2.8%) | (5.8%) | 36% |
|
| EPS (5yr) | 13.4% | 11.4% | 52 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (18.8%) | (16.3%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.670) | ($2.620) | ($1.150) | |
| Month Ago EPS | ($0.670) | ($2.620) | ($1.150) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.667) | ($2.467) | $4.800 | |
| Year/Year Chg | (30.8%) | (40.1%) | (78.3%) | |
| Financials | VNRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $152 | 4% |
|
| Net Income (TTM) (Mil) | ($25) | ($10) | 22% |
|
| EPS (TTM) | ($4.201) | ($0.500) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($21) | ($2) | 14% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $1 | 45% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $22 | 26% |
|
| Enterprise Value (Q1) (Mil) | $19 | $304 | 11% |
|
| Valuation | VNRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.80 | na |
|
| P/E | na | 31.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | VNRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 59.1% | 96% |
|
| Net Margin | (997.5%) | (7.3%) | 0% |
|
| ROA | (280.2%) | (13.7%) | 1% |
|
| ROE | 82.3% | (15.8%) | 95% |
|
| Liabilities to Assets | 469.2% | 44.7% | 100% |
|
| F-Score | 3 | 4 | 19% |
|
VolitionRx Limited did not pass any screens on 7/31/2026.
